Microperimetric changes after intravitreal bevacizumab for exudative age-related macular degeneration

Acta Ophthalmologica

Volumn 86, Issue 6, 2008, Pages 696-697

  Rensch, Florian ^a   Jonas, Jost B ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

AGED; CASE REPORT; CENTRAL SCOTOMA; FEMALE; FOLLOW UP; HUMAN; LETTER; OFF LABEL DRUG USE; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PERIMETRY; PRIORITY JOURNAL; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RETINA NEOVASCULARIZATION; VISUAL ACUITY; VISUAL FIELD; VISUAL IMPAIRMENT;

EID: 51049114273     PISSN: 1755375X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0420.2007.01131.x     Document Type: Letter

References (5)

1. Emerson MV, Lauer AK, Flaxel CJ et al. (2007): Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 27: 439-444.
2. Ergun E, Maar N, Radner W, Barbazetto I, Schmidt-Erfurth U & Stur M (2003): Scotoma size and reading speed in patients with subfoveal occult choroidal neovascularization in age-related macular degeneration. Ophthalmology 110: 65-69.
3. Midena E, Raddin PP, Pilotto E, Ghirlando A, Convento E & Varano M (2004): Fixation pattern and macular sensitivity in eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. A microperimetry study. Semin Ophthalmol 19: 55-61.
4. Schmidt-Erfurth UM, Elsner H, Terai N, Benecke A, Dahmen G & Michels SM (2004): Effects of verteporfin therapy on central visual field function. Ophthalmology 111: 931-939.
5. Yoganathan P, Deramo VA, Lai JC, Tibrewala RK & Fastenberg DM (2006): Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 26: 994-998.